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Background: More than 20% of the hip fracture patients die within the first year after the incident. Few data are
available on the trends in mortality following a hip fracture. The present aim was to study changes in excess
mortality after hip fracture from 1978/79 up to 1996/97.
Methods: Data on 5180 hip fracture patients aged ≥ 50 years, identified in three earlier, well validated, incidence
studies from Oslo were used. The studies took place in the two years periods 1978–79 and 1989–89 and in a one
year period from 1st of May 1996 to 30th of April 1997. The study was designed as a historic cohort study.
Exposure was sustaining a hip fracture in the registration periods. Outcome was death of all causes. Age- and
sex-specific one year-mortality rates were provided by Statistics Norway. Standardized mortality ratios (SMR) were
calculated for the three cohorts for each sex and age-group, for the 0–6 months, 6–12 months, 0–1 year, 1–5 years
and 5–10 years intervals after fracture. To assess the duration of the excess mortality in hip fracture patients,
time-framed Kaplan-Meier curves for consecutive 5-years intervals were conducted for the hip fracture patients
and the corresponding background population. Only patients still alive at the start of the time interval were
included. One sample log rank tests were used to test for statistical significance.
Results: The one-year SMR ranged from 3.64 (2.82 – 4.61) to 4.53 (3.67 – 5.54) in men and from 2.78 (2.39 – 3.19) to
3.60 (3.19 – 4.05) in women. In the 0–6 months interval a reduction in SMR from 1978/79 to 1996/97 was observed
in women aged ≥85 years. The duration of excess mortality ranged from two years in men ≥85 years to more than
ten years in men and women aged 65–84 years.
Conclusion: Excess mortality among hip fracture patients remains high. Over the decades, a reduced excess
mortality was mainly seen in the oldest patients, suggesting that specific efforts intending to improve prevention
and treatment of osteoporosis and osteoporotic fractures in the youngest elderly are required.Background
Hip fractures are associated with high morbidity and mor-
tality [1-3]. Most studies over the last five decades report a
one-year mortality ranging from 15-30% [4-9], and the
mortality tends to be higher in men than in women [8,10].
The highest mortality is observed within the first 6 months
after the fracture and declines thereafter [5,6,10].
Whereas the relative excess mortality in hip fracture
patients is highest among the youngest, the absolute* Correspondence: trine_finnes@yahoo.com
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reproduction in any medium, provided the orexcess mortality is highest among the oldest [5]. The ex-
cess mortality is associated with both pre-existing comor-
bidity and fracture related complications e.g. infections
and delirium [1,6,11,12]. Few studies on secular trends
and changes in excess mortality after hip fractures over a
prolonged period are available and the results are
conflicting [5,8,9,11,13]. In addition, the duration of the
period with excess mortality is uncertain [9,11,13].
Oslo, the capital of Norway, has the highest reported
incidence of hip fracture world-wide [14]. The incidence
has been reported every decade since the 1970’ies
[14-16]. However, reports on mortality after hip fractures
for this area are limited [6]. The present aim was to
study secular trends in excess mortality after hip fracture
in Oslo in the period of 1978–1997.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population
Data from three earlier incidence studies on hip frac-
ture in Oslo were used [14-16]. These studies include
all patients ≥20 years with hip fracture in the two-year
periods 1978 to 1979 (n=2067) and 1988 to1989
(n=2697), and in the one-year period from 1st of May
1996 until 30th of April 1997 (n=1290). Hip fractures
(International Classification of Diseases, ninth revision
(ICD-9) code 820.X) were identified through diagnosis
registers, operating theatres protocols, medical records,
and x-ray records. Fractures in patients residing out-
side Oslo or fractures due to malignancy were not in-
cluded in these studies.
Hip fractures in patients aged <50 years are infrequent,
and the younger hip fracture patients differ considerably
from the older hip fracture patients regarding comorbid-
ity [17,18]. For this reason, patients aged <50 years were
not included in the current study. For patients with
more than one fracture in any of the inclusion periods,
the first fracture was included in the present study.
Registration cards from the incidence studies of 1978/
79 and 1988/89 were retrieved, and the cases were iden-
tified through name and date of birth. The data from the
registration cards were transferred into an electronic
register, and linked to the National Population Register
(Norwegian Tax Administration, Oslo) to achieve the full
unique Norwegian 11-digit identification number for each
patient. The data from 1996/97 were stored in an elec-
tronic register with the 11-digit identification number.
In the 1978/79-cohort, 50 patients were aged <50 years.
Of the patients aged ≥50 years, 80 patients were not in-
cluded due to: I) unidentifiable date of fracture (n=53);
II) loss to follow up (n=1); III) missing unique identifica-
tion number (n=24); IV) fracture due to metastasis
(n=1); V) double registration (n=1). There were no dif-
ferences regarding sex, age, and type of fracture when
comparing the excluded patients with the included pa-
tients (Chi-square test and Student’s t test).Table 1 Characteristics of the included patients of the differe
1978/79
Included, n 1937
Men, n (%) 215 (21.5)
Mean age at time of fracture, men (95% CI) 74.2 (73.3 – 75.2)
Mean age at time of fracture, women (95% CI) 76.8 (76.4 – 77.3)
50-64 years, n (%) 254 (13.1)
65-84 years, n (%) 1322 (68.2)
≥85 years, n (%) 361 (18.6)
Intertrochanteric fractures, n (%) 751 (38.8)
Median follow up time, years (range) 4.9 (0–30.0)
* p-value for differences between the cohorts.In the 1988/89-cohort, 26 patients who had sustained
a hip fracture in the previous inclusion period and 42
patients aged <50 years were not included. In addition,
ten patients were not included due to: I) unidentifiable
date of fracture (n=2); II) loss to follow up (n=4); III)
missing unique identification number (n=3); IV) resident
outside Oslo (n=1).
In the 1996/97 cohort, 15 patients had sustained a hip
fracture in one of the earlier inclusion periods, and 21
patients were aged <50 years. All the remaining patients
were included.
Data from the 5180 cases included (Table 1) were
linked to The Cause of Death Register provided by Sta-
tistics Norway (Statistics Norway, Kongsvinger, Norway).
The patients were followed up with respect to death
from all causes until 31st of December 2007 (Additional
file 1: Flow chart).
Study design
The study was designed as a historic cohort study. Ex-
posure was sustaining a hip fracture in the registration
periods. Outcome was death from all causes. Covariates
were sex, age, and type of fracture.
Data and definitions
The hip fractures were defined as femoral neck or
intertrochanteric. Subtrochanteric fractures were not
included.
Hip fractures in patients aged ≥65 years are often referred
to as geriatric hip fractures, and younger patient are fre-
quently not included in survival studies [8,13]. Those aged
≥ 85 years have a high absolute mortality during the first
six months of follow up, and a shorter duration of excess
mortality than younger hip fracture patients [5,7,9]. The pa-
tients were therefore divided into following age groups: I)
50–64 years; II) 65–84 years; and III) ≥ 85 years.
In the 1978/79-cohort, fracture time was only regis-
tered by month and year. Date of fracture was conse-
quently set to the first of the month to avoid negativent cohorts
1988/89 1996/97 p-value*
2619 1254
546 (20.8) 279 (22.2) 0.597
76.6 (75.9 – 77.4) 79.5 (78.4 – 80.6) <0.001
80.2 (79.8 – 80.6) 81.4 (80.9 – 82.0) <0.001
170 (6.5) 60 (4.8)
1606 (61.3) 719 (57.3)
843 (32.2) 475 (37.9)
1085 (41.4) 563 (44.9) 0.003
3.37 (0–20.0) 3.63 (0–11.7)
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ture date, survival analyses with the fracture date set to
both the 1st and the 15th of the month were performed.
The different fictive fracture days did not influence the
results presented.Statistical analyses
Comparisons of baseline data between the three cohorts
were made using the Kruskal Wallis test and the One-Way
-ANOVA. Kaplan-Meier-curves were estimated for each
cohort stratified by sex, age group, and fracture type.
Age- and sex-specific one year-mortality rates for Oslo
from 1978–2007 were provided by Statistics Norway and
were used to calculate the expected survival curves for each
cohort (Figure 1) as described by Therneau [19].
Standardized mortality ratio (SMR) expresses the
level of excess mortality [20], and was calculated as the
ratio of patient mortality to mortality in the back-
ground population of Oslo. The background popula-
tion corresponded to the study population with respect
to time period, sex, and year of birth. SMRs were cal-
culated for the three cohorts for each sex, age-group,
and fracture type, for the 0–6 months, 6–12 months,
0–1 year, 1–5 years and 5–10 years intervals after frac-
ture. Sex- and age stratified analyses were also
performed for the 0–1 year interval to allow compari-
son with earlier studies. Confidence intervals for SMR
were computed as bootstrap BCa intervals with 10 000
replications [21].
To assess the duration of the excess mortality, time-
framed Kaplan-Meier curves for 5-years intervals
starting at each year of the follow up time were calcu-
lated for each sex and age-group. These curves were
compared with the corresponding expected survival
curves. Only patients still alive at the start of the time
interval were included. One sample log rank tests were
used to test for statistical significance between ob-
served and expected curves. The beginning of the last
5 year interval, where there still was statistical signifi-
cance between the expected and observed curves, was
set as duration of excess mortality.
The level of statistical significance was set at p<0.05.
Analyses were performed using SPSS 14.0 (SPSS Inc.,
Chicago, IL, USA) and R 2.10.1 (The R Foundation for
Statistical Computing, Vienna, Austria) with the R pack-
ages survival and boot.Ethics and approvals
The study is performed in compliance with the Helsinki
Declaration. The Regional Committee for Research Eth-
ics approved the study. A dispensation from profes-
sional secrecy was given by the Norwegian Directorate
for Health and Social Affairs. Permission to handlesensitive information were sought and received from
the Data Protection Agency.Results
Patient characteristics
The proportion of men was 21-22% in all three cohorts
(Table 1). Mean age at time of fracture increased by about
5 years in both men and women from 1978/79 to 1996/
97. The proportion of patients aged ≥ 85 years increased
from 19 to 38%. The proportion of intertrochanteric frac-
tures was higher in the 1996/97-cohort than in the
1978/79-cohort (p=0.003).Excess mortality within each cohort
Kaplan-Meier curves of the three cohorts showed a sub-
stantially higher mortality for both sexes, in all age
groups, than did the expected survival curves (Figure 1).
One-year mortality in the different cohorts ranged
from 30% to 33% in men, and from 21% to 25% in
women (data not shown).
The highest SMR was observed within 6 months after
the fracture (Tables 2, 3, 4).
Men had higher SMR than women during all follow
up intervals and in all three cohorts.
The SMRs were higher in those aged 65–84 years than
in those aged ≥85 years during all follow up intervals
and in all three cohorts (Table 3). There were no sub-
stantial differences in SMRs of femoral neck and
intertrochanteric fractures within the cohorts (Table 4).
Sex stratified analyses for each age group demonstrated
higher SMR in men than in women in patients aged 56–
84 and ≥ 85 years (Table 5). The lowest SMR was seen
in the oldest age group in both sexes.Secular changes in excess mortality from 1978 to 1997
Changes in SMRs over the decades were more evident
during the 0–6 month interval, than during long term
follow up (Tables 2, 3, 4).
In women, there was a reduction in SMR from 1978/
79 to 1996/97 during the 0–6 month interval. In men, a
similar trend was observed (Table 2). In the age stratified
analyses a statistically significant reduction in SMR from
1978/79 to 1996/97 was evident in the 0–6 months
interval in those aged ≥85 years (Table 3). Further age-
and sex stratified analyses performed for the 0–1 year
interval revealed a statistically significant reduction in
SMR only in women aged ≥85 years and a trend towards
declining SMR in men aged 65–84 years (Table 5).
The changes in SMR from 1978/79 to 1996/97 were
similar for femoral neck and intertrochanteric fractures
(Table 4).
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Figure 1 (See legend on next page.)
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Figure 1 Expected survival and observed survival by cohort. Expected survival (dotted curves) and observed survival (continuous curves) by
cohort. a) All, b) Men, c) Women, d) Patients aged 50–64 years, e) Patients aged 65–84 years, and f) Patients aged ≥85 years (Please note slight
difference in the time scale). A substantially higher mortality in hip fracture patients, than in the corresponding background population, is shown.
The better survival in the 1978–79 cohort in the analyses not stratified on age is explained by the younger patients in this cohort.
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The longest duration of excess mortality was found in
women aged 65–84 years (Table 6), where the excess
mortality lasted more than 19 years in the 1978/79-co-
hort, for 14 years in the 1988/89-cohort, and until end
of follow up in the 1996/97-cohort. The shortest
period with excess mortality was seen in men aged
≥85 years. In this age-group, the mortality returned to
the level of the background population after two toTable 2 Standardized mortality rates in given time intervals w
Follow up time Sex Cohort n
0-6 months
Men
78/79 417
88/89 546
96/97 279
Women
78/79 1520
88/89 2073
96/97 975
6-12 months
Men
78/79 312
88/89 409
96/97 207
Women
78/79 1271
88/89 1702
96/97 819
1-5 years
Men
78/79 291
88/89 371
96/97 188
Women
78/79 1195
88/89 1554
96/97 749
5-10 years
Men
78/79 162
88/89 163
96/97 93
Women
78/79 790
88/89 853
96/97 407four years. Except for women aged ≥85 years, there
was a trend towards shorter duration of excess mortal-
ity from 1978/79 to 1996/97.
Discussion
The present study demonstrates considerable excess
mortality for a prolonged period after hip fracture. In
the period from 1978/79 to 1996/97, excess mortality
during the first six months after the fracture declinedith respect to sex and cohort
Dead, n (%) Expected dead, n SMR (95% CI)
105 (25.2) 15.41 6.81 (4.47 – 8.35)
137 (25.1) 22.96 5.97 (4.90 – 7.13)
72 (25.8) 14.00 5.14 (3.90 – 6.61)
249 (16.4) 48.74 5.11 (4.44 – 5.80)
371 (17.9) 89.67 4.14 (3.68 – 4.61)
156 (16.0) 43.36 3.60 (2.99 – 4.26)
21 (6.7) 12.41 1.69 (1.02 – 2.48)
38 (9.3) 18.80 2.02 (1.38 – 2.70)
19 (9.2) 11.03 1.72 (1.00 – 2.59)
76 (6.0) 41.45 1.83 (1.42 – 2.28)
148 (8.7) 75.42 1.96 (1.65 – 2.30)
70 (8.5) 38.19 1.83 (1.42 – 2.29)
129 (44.3) 71.90 1.79 (1.47 - 2.18 )
208 (56.0) 97.95 2.12 (1.82 – 2.47)
95 (50.5) 60.43 1.57 (1.26 – 1.96)
405 (33.9) 285.68 1.42 (1.27 - 1.57)
701 (45.1) 472.31 1.48 (1.37 - 1.61)
342 (45.7) 245.99 1.39 (1.24 - 1.55)
83 (51.2) 54.17 1.53 (1.14 – 2..04)
88 (54.0) 54.77 1.61 (1.25 – 2..06)
58 (62.3) 33.56 1.73 (1.32 – 2.26)
366 (46.3) 255.16 1.43 (1.28 – 1.60)
455 (53.3) 318.87 1.42 (1.29 – 1.58)
258 (63.3) 146.69 1.76 (1.54 – 2.02)
Table 3 Standardized mortality rates in given time intervals with respect to age group and cohort (both sexes)
Follow up time Age-group, years Cohort n Dead, n (%) Expected dead, n SMR (95% CI)
0-6 months 50-64
78/79 254 7 (2.7) 1.3 5.25 (1.62 – 9.57)
88/89 170 10 (5.9) 1.0 10.54 (4.53 – 17.86)
96/97 60 4 (6.7) 0.2 17.19 (3.66 – 37.53)
65-84
78/79 1322 223 (16.9) 35.2 6.33 (5.49 – 7.20)
88/89 1606 257 (16.0) 40.9 6.29 (5.49 - 7.15)
96/97 719 107 (14.9) 17.8 6.03 (4.88 – 7.28)
≥ 85
78/79 361 124 (34.3) 27.6 4.49 (3.67 – 5.38)
88/89 843 241 (28.6) 70.8 3.40 (2.94 – 3.90)
96/97 475 117 (24.6) 39.4 2.97 (2.43 – 3.60)
6-12 months 50-64
78/79 247 4 (1.3) 1.33 2.99 (0.68 – 16.25)
88/89 160 3 (1.9) 0.90 3.35 (0.00 -7.86)
96/97 56 1 (1.8) 0.22 4.54 (0.00-16.35)
65-84
78/79 1099 64 (30.1) 30.14 2.12 (1.62 – 2.67)
88/89 1349 102 (7.6) 36.64 2.78 (2.26 -3.33 )
96/97 612 39 (6.4) 16.03 2.43 (1.70 -3.24 )
≥ 85
78/79 237 29 (12.2) 22.39 1.30 (0.85- 1.81)
88/89 602 81 (13.5) 56.68 1.43 (1.13 – 1.76)
96/97 358 49 (13.7) 32.97 1.49 (1.09 – 1.93)
1-5 years 50-64
78/79 243 31 (12.8) 11.79 2.63 (1.75 -3.59 )
88/89 157 28 (17.8) 7.41 3.78 (2.46 – 5.31)
96/97 55 7 (12.7) 2.03 3.45 (1.12 – 6.47)
65-84
78/79 1035 363 (35.1) 224.54 1.62 (1.45 – 1.80)
88/89 1247 533 (42.7) 260.07 2.05 (1.87 - 2.24)
96/97 573 226 (39.4) 120.21 1.88 (1.64 – 2.15)
≥ 85
78/79 208 140 (0.67) 121.25 1.36 (0.97 – 1.37)
88/89 521 348 (66.8) 302.79 1.15 (1.03 – 1.28)
96/97 309 204 (66.0) 184.18 1.11 (0.97 - 1.27)
5-10 years 50-64
78/79 212 36 (17.0) 17.94 2.01 (1.38 – 2.74)
88/89 129 28 (21.7) 9.99 2.80 (1.81 – 3.93)
96/97 48 10 (20.8) 2.91 3.44 (1.51 – 5.91)
65-84
78/79 672 359 (53.4) 233.11 1.54 (1.38 – 1.72)
88/89 714 363 (50.8) 233.4 1.55 (1.40 – 1.73)
96/97 347 213 (61.4) 106.23 2.01 (1.74 – 2.31)
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Table 3 Standardized mortality rates in given time intervals with respect to age group and cohort (both sexes)
(Continued)
≥ 85
78/79 68 54 (79.4) 58.29 0.93 (0.66 – 1.32)
88/89 173 152 (87.9) 130.22 1.17 (0.98 – 1.38)
96/97 105 93 (88.6) 71.11 1.31 (1.07 – 1.61)
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other age groups, no statistically significant changes were
seen. The duration of excess mortality ranged from 2 years
in men aged ≥ 85 years to more than 10 years in women
aged 65–84 years.Table 4 Standardized mortality rates in given time intervals w
Follow up time Fracture type Cohort n
0-6 months Femoral neck
78/79 1185
88/89 1534
96/97 691
Inter-trochanteric
78/79 751
88/89 1085
96/97 563
6-12 months Femoral neck
78/79 982
88/89 1271
96/97 564
Inter-trochanteric
78/79 600
88/89 840
96/97 462
1-5 years Femoral neck
78/79 921
88/89 1166
96/97 518
Inter-trochanteric
78/79 564
88/89 759
96/97 419
5-10 years Femoral neck
78/79 609
88/89 639
96/97 294
Inter-trochanteric
78/79 343
88/89 377
96/97 206Excess mortality
The observed 1-year SMRs in the present study tended
to be higher than in other similar reports. One study on
hip fracture caused by falls from standing height or less
in patients aged > 60 years showed a 1-year SMR ofith respect to fracture type and cohort (both sexes)
Dead, n (%) Expected dead, n SMR (95% CI)
203 (17.1) 36.7 5.53 (4.76 – 6.37)
263 (17.1) 62.6 4.20 (3.66 – 4.76)
127 (18.4) 30.2 4.21 (3.44 – 5.05)
151 (20.1) 27.4 5.51 (4.61 – 6.52)
245 (22.6) 50.0 4.90 (4.23 – 5.63)
101 (17.9) 27.2 3.71 (2.95 – 4.56)
61 (6.2) 30.55 2.00 (1.50 – 2..52)
105 (8.3) 51.89 2.02 (1.64 – 2.43)
46 (8.2) 25.53 1.80 (1.30 – 2.36)
36 (6.0) 23.31 1.54 (1.05 – 2.10)
81 (9.6) 42.33 1.91 (1.51 – 2.36)
43 (9.3) 23.69 1.82 (1.29 – 2.41)
312 (33.9) 205.26 1.52 (1.32 – 1.71)
527 (45.2) 325.74 1.62 (1.47 – 1.77)
224 (43.2) 161.04 1.39 (1.21 – 1.60)
221 (39.2) 152.31 1.45 (1.25 – 1.67)
382 (50.3) 244.52 1.56 (1.39 – 1.75)
213 (50.8) 145.39 1.47 (1.27 – 1.69)
260 (42.7) 191.54 1.36 (1.19 – 1.54)
322 (50.4) 229.64 1.40 (1.25 – 1.57)
176 (59.9) 99.77 1.76 (1.52 – 2.07)
189 (55.1) 117.78 1.60 (1.35 – 1.90)
221 (58.6) 144.01 1.53 (1.32 – 1.79)
140 (68.0) 80.48 1.74 (1.45 – 2.10)
Table 5 Standardized mortality rates for the 0–1 year interval after fracture with respect to sex and cohort
Age-group, years Cohort n Dead, n (%) Expected dead, n SMR (95% CI)
Men 50-64
78/79 74 3 (4.1) 1.26 2.38 (0.00 - 5.58)
88/89 63 5 (7.9) 0.99 5.05 (1.02 - 10.42)
96/97 22 2 (9.1) 0.23 8.76 (0.00 - 26.70)
65-84
78/79 281 93 (33.1) 17.13 5.43 (4.30 - 6.74)
88/89 363 117 (32.2) 22.19 5.27 (4.27 - 6.41)
96/97 170 43 (25.3) 10.92 3.94 (2.76 - 5.29)
≥ 85
78/79 62 30 (48.4) 3.18 3.18 (2.00 – 4.93)
88/89 120 53 (44.2) 2.85 2.85 (2.07 – 3.84)
96/97 87 46 (52.9) 3.31 3.31 (2.30 – 4.70)
Women 50-64
78/79 180 8 (4.4) 1.41 5.67 (2.10 – 10.02)
88/89 107 8 (7.5) 0.85 9.36 (3.42 – 16.76)
96/97 38 3 (7.9) 0.22 13.37 (0.00 – 32.24)
65-84
78/79 1041 194 (18.6) 48.22 4.02 (3.45 – 4.64)
88/89 1243 242 (19.5) 55.33 4.37 (3.82 – 4.97)
96/97 549 103 (18.8) 22.86 4.51 (3.62 – 5.48)
≥ 85
78/79 299 123 (41.1) 40.56 3.03 (2.46 – 3.68)
88/89 723 269 (37.2) 108.90 2.47 (2.16 – 2.82)
96/97 388 120 (30.9) 58.47 2.05 (1.69 – 2.46)
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only including cognitively intact, ambulatory patients
aged ≥65 years reported an overall 1-year SMR of 1.5 [8].
The present study includes practically all hip fracture pa-
tients aged >50 years in Oslo, including those living in
nursing homes. Holvik et al. reported a one-year mortality
of 46% in patients admitted from nursing homes, com-
pared with 13.7% in patients living at home at the time of
fracture [23]. In the present study, place of living is not reg-
istered in all three cohorts. However, in the 1988–89 co-
hort, 24% of the patients stayed in nursing home at the
time of the fracture. Thus, the higher mortality among
nursing home residents may have contributed to the high
SMR in the current study. By also including those aged
50–65 years, average SMR is expected to increase because
of the high relative excess mortality in this age group.
Excess mortality according to age
The higher relative excess mortality among the youngest
compared with the oldest is in accordance with other re-
ports [5,7,24]. The high impact of hip fracture on rela-
tive excess mortality among the youngest is probably
related to the low mortality in the correspondingpopulation, and the higher frequency of comorbidity in
young hip fracture patients compared with the back-
ground population with same age [6,18,25,26].
Excess mortality according to sex
As in other reports, we found a higher excess mortality
in men compared with women [5,8,10,27]. Higher excess
mortality in men is also reported in studies adjusting for
the higher rates of complications and comorbidity [6,10].
The reasons for the higher excess mortality in men re-
main unclear.
Excess mortality according to time after fracture
The highest excess mortality occurred within the first six
months after the fracture, in accordance with earlier re-
ports [5,6,11]. The high mortality in this period is prob-
ably a combined effect of the trauma and comorbidity
[6,11]. The lower SMR during long-term follow up is to
be expected, as the impact of trauma declines with time.
Secular changes of excess mortality
Earlier reports on changes in mortality over the decades
have been conflicting. A population-based British study
Table 6 Duration of excess mortality according to sex,
age-group, and cohort
Sex Age-group,
years
Cohort Included, n Duration of excess
mortality, years
Men
50-64 78/79 74 6
88/89 63 9
96/97 22 3
65-84 78/79 281 15 a)
88/89 363 11
96/97 170 >10 b)
≥ 85 78/79 62 3
88/89 120 3
96/97 87 2
Women 50-64 78/79 180 17
88/89 107 12
96/97 38 9
65-84 78/79 1041 >19 a)
88/89 1243 14
96/97 549 10
≥ 85 78/79 299 3
88/89 723 7
96/97 388 8
a) Further analysis not possible due to few patients left.
b) End of follow up at 10.7 years.
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1983, but no reduction from 1983 to 1998 [13]. Fur-
thermore, a Danish register study reported a slightly in-
creased excess mortality in hip fracture patients in the
period 1986 to 2001 compared with 1981 to 1985 [9].
The methods used in these studies differ from the
present one, which limit the possibility for comparison
of the results.
Secular changes of excess mortality according to age
The present data showed a statistically significant re-
duction in the 0–6 month SMR from 1978/79 to
1996/97 in patients aged ≥ 85 years. Decreased mor-
tality following pneumonia and myocardial infarction
[28-31], which are common concomitant diseases in
old hip fracture patients [12], may have contributed
to the improved survival in the oldest age group. One
may speculate that an increasing disease burden in hip
fracture patients aged < 85 years, may be a reason for
the stable SMR over time in these age groups. These
speculations are supported by data from 2005 – 2009
from the Norwegian hip fracture register, which shows
an increased proportion of patients with an ASA-
(American Society of Anaesthesiologists) score [32] of
3 (severe systemic disease) at admittance, and fewerwith an ASA score of 1 and 2 (none or mild systemic
disease) [33]. It is not known when this trend started.
Secular changes of excess mortality according to sex
Although more pronounced in women than in men,
there was a similar reduction in the excess mortality for
both sexes during the 0–6 months interval from 1978/79
to 1996/97 in the analyses stratified on sex (Table 2).
However, during the 6–12 months and the 1–5 years
interval there was a trend towards increased SMR from
1978/79 to 1988/89 and a reduction from 1988/89 to
1996/97 in men, which was not found in women. The
present data do not provide any explanation for this.
Changes in incidence of, and survival after diseases more
common in men than in women might have influenced
the outcome in men [28,34]. Furthermore, Bacon et al.
found a greater improvement of survival in elderly men
than in women in the period 1965 to 1993 [35]. This
highlights the need for separate analyses of mortality in
men and women.
Secular changes of excess mortality according to time
after fracture
The present data show that secular changes in SMR are
most pronounced during short time follow up. This is to
be expected, as the excess mortality is highest in the
early phase after the fracture. Modifiable factors which
could improve survival are time from fracture to oper-
ation [36], the use of prophylactic antibiotics [37], and
early mobilisation [38].
Secular changes of excess mortality according to fracture
type
Patients suffering from intertrochanteric fractures are
supposed to be frailer and have more comorbidity and a
higher mortality than those with femoral neck fractures
[39], and the increased proportion of intertrochanteric
fractures in our study could have influenced the results.
However, in the present study, the SMRs were similar
for the two fracture types, implying that fracture type is
not a major determinant of excess mortality. The results
are in concordance with other studies that have shown
that the age- adjusted mortality in patients with
intertrochanteric fractures is the same as for those with
femoral neck fractures [40,41].
Secular changes of duration of excess mortality
Duration of the period with excess mortality ranged from
two years to more than 19 years in the different sex- and
age-groups. Hip fracture patients aged 65–84 years had,
in accordance with other population based studies [5,11],
the longest duration of excess mortality. This prolonged
period of excess mortality may reflect the high rate of co-
morbid conditions also among those surviving the first
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other studies reporting prolonged excess mortality only
in patients with a high degree of comorbidity [6,11]. It is
to expect that the oldest patients have the shortest period
of excess mortality, as a high proportion in this age group
will die during the follow up. However, the present study
demonstrated an increase from 3 to 8 years of the period
with excess mortality among the oldest women. Expected
remaining life-time in Norwegian women aged 85 years
was 5.9 years in 1996 according to the data provided
from Statistics Norway, and changes in duration of ex-
cess mortality are therefore considered to be of clinical
relevance. The increased duration of excess mortality
may be a result of the reduced 6-months and 1-year ex-
cess mortality observed in hip fracture patients ≥85 years,
which may have left a higher number of frail and sick pa-
tients for the long term follow up, contributing to excess
mortality for a longer time period. Contrary, the shorter
duration of excess mortality in men compared with
women, may reflect the higher early mortality in men,
leaving few and relatively healthy subjects for follow up.Limitations
Although, SMRs allow comparison of mortality in co-
horts from populations with different background mor-
tality, it may be considered as a limitation that no data
on comorbidity or medication were available. Hip frac-
ture patients are likely to have a higher frequency of
comorbidity than the general population [6,11,18,25],
and changes in disease burden and medication in the
fracture population may have differed from that in the
background population. Another limitation of the study
is that data were collected for only one calendar year in
1996/97, influencing the statistical power, particularly
in men and the younger patients.
The strengths of the present study are the complete-
ness of registrations of deaths and the long follow up of
hip fracture patients from validated population-based in-
cidence studies over three decades. No major changes in
diagnostics took place in the actual period. The defini-
tions remained the same, and the data collection was
equal in the three incidence studies [14-16]. No elec-
tronic diagnosis registers were available in 1978/79.
However, the additional identification of the hip frac-
tures through medical records and x-rays in all three in-
cidence studies makes the data collection accurate and
comparable in all three studies [14].Conclusion
To conclude, hip fracture patients have a considerably
higher mortality than the background population with
same age and gender. Over the decades, a statisticallysignificant reduction of one year excess mortality was only
seen in the oldest women, suggesting that specific efforts
intending to improve prevention and treatment of osteo-
porosis and osteoporotic fractures in the youngest elderly
are required. Mortality studies including more recent
data with a higher proportion of patients treated with
bisphosphonates and hip replacement are warranted.
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